# Genetic Polymorphism of the Glutathione S-Transferase M1 and Development of Breast Cancer

Iraj Saadat<sup>1</sup>, Shahpour Omidvari<sup>2</sup> and Mostafa Saadat<sup>\*1</sup>

<sup>1</sup>Dept. of Biology, College of Sciences, Shiraz University, Shiraz; <sup>2</sup>Dept. of Radiotherapy, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

#### ABSTRACT

Glutathione S-transferases (GSTs) are encoded by a superfamily of genes and play a role in the detoxification of potential carcinogens. The human GSTs are divided into four classes: alpha, mu, pi and theta. Previous studies indicated that the absence of the Glutathione S-Transferase M1 (GSTM1) protein correlated with an increased risk of developing some types of cancers. Association between specific genotype and the development of breast cancer is still an open question. In the present study, the association between genetic polymorphism in the GSTM1 and susceptibility to breast cancer was investigated. The genetic polymorphism of the GSTM1 in exon 5 to exon 6 segments was detected by PCR in 59 patients with breast cancer and 59 normal subjects. The frequency of the GSTM1 null genotype in control and patient groups was 39.0% and 50.8% respectively. There was no significant association between null genotype of the GSTM1 and susceptibility to breast cancer ( $X^2 = 1.63$ , df = 1, p > 0.05). *Iran. Biomed. J. 5 (1): 21-25, 2001* 

Keywords: Breast cancer, Glutathione S-transferase M1, Polymorphisms

#### **INTRODUCTION**

oth genetic and environmental factors are involved in the development of cancer. The environment gene interaction on carcinogenesis has been well demonstrated by phase I and phase II enzymes that are involved in the metabolism of the carcinogens. The phase I enzymes, cytochrome P450 (CYPs), activate many environmental procarcinogens by adding or exposing their functional groups [1]. The phase II enzymes, including glutathione S-transferase (GST) (E.C. 2.5.1.18) and N-acetyl transferase, are involved in the detoxification of activated metabolites of the carcinogens [2].

The human GST is a family of multifunctional enzymes that catalyzes the conjugation reaction between reduced glutathione and a variety of electrophiles [3]. The GSTs are divided into four classes: alpha, mu, pi and theta based on amino acid sequence similarity and antibody cross-reactivity [4]. In human, hereditary differences in the specific GST activities are due to the genetic polymorphisms [5, 6].

One member of the  $GST\mu$  class, GSTM1, is involved in the detoxification of tobacco-related

Several studies have shown that GSTM1 null genotype is associated with an increased risk of lung, bladder, gastric, colorectal, skin, breast and laryngeal cancers, and acute lymphocytic leukemia [10-18]. Whereas, other studies did not find a significant association between subjects lacking GSTM1 activity and the risk of developing breast cancer [17-19]. Thus the relationship between GSTM1 null genotype and susceptibility to breast cancer is still an open question.

In the present study, we employed PCR-based genotyping method to examine the GSTM1 polymorphism. We studied a control group of healthy blood donors to know the null genotype frequency in the general population and a group of breast cancer patients to evaluate the possible role of the GSTM1 null genotype in breast cancer susceptibility.

carcinogens, such as epoxides and hydroxylated metabolites of benzo (a) pyrene [7]. The GSTM1 is polymorphic in human and three alleles have been described: two functional alleles (GSTM1\*A and GSTM1\*B) and a non-functional null-allele (GSTM1\*0) [8, 9]. The GSTM1\*0 allele has been shown to be the result of a deletion of the entire GSTM1 gene [5].

## MATERIALS AND METHODS

Blood sampling and extraction of DNA. Blood samples (5 ml taken into EDTA at venipuncture) were obtained from 59 patients bearing histologically proven breast cancer (mean age: 46.0 + 10.6; range: 27 to 68) in the Nemazi Hospital in Shiraz, Iran. Affected patients were recruited before or at the beginning of the radio- or chemotherapy treatment. Control blood samples were obtained from 59 healthy females (mean age: 39.8 + 15.1; range: 25 to 75). Both patients and control groups were unrelated Iranian Muslims. Immediately after collection, whole blood was stored at -20°C until use. The genomic DNA for PCR was isolated from whole blood using the thawed blood samples by the standard procedure [20].

At the time of blood donation, participants completed a brief questionnaire that ascertained smoking status, medication taken, age, alcohol consumption, and family history for malignancies.

Polymerase chain reaction (PCR). Primers for amplifying GSTM1 segment the gene corresponding to exon 5, intron 5, and exon 6 were 5'AGACAGAAGAGGAGAAGATTC3' and 5'TCCAAGTACTTTGGCTTCAGT3' [5]. PCR was performed in 50 µl reaction buffer containing 200 µM dNTP, 1.5 mM, 1 µm primers, about 1 µg DNA and 2 units of thermostable Taq DNA polymerase using a programmable thermocycler (Progene, Techne, England). After 5 min of pretreatment at 94°C, 35 cycles of 1.5 min denaturation at 94°C, 1.5 min annealing at 61°C and 1 min extension at 72°C were performed. For evaluating the GSTM1 polymorphism, the amplification products were analyzed by gel electrophoresis (1.6% agarose). This technique dose not distinguish between heterozygote and homozygote GSTM1-positive genotypes, but it conclusively identifies null genotype. To ensure laboratory quality control, two independent readers interpreted the gel photographs. Any sample with ambiguous results (generally due to low PCR yield) was retested, and a random selection of 15% of all samples was repeated. No discrepancies were discovered upon replicate testing.

Statistical analysis. The statistical significance of difference for frequency of the null genotype between patient and control groups was tested by chi-square analysis. A probability of p<0.05 considered statistically significant.

### **RESULTS AND DISCUSSION**

The amplified region between exons 5 and 6 including intron 5 clearly showed a single band of around 900 bp after 1.6% agarose gel electrophoresis, as reported previously [17, 18] (Fig. 1). The absence of amplified product was consistent with the null genotype.



**Fig. 1.** PCR for GSTM1 null and GSTM1 positive genotype identification: Agarose gel (1.6%) electrophoresis showing the 900 bp DNA fragment amplified from GSTM1. Lanes 1-3; healthy controls, Lanes 4-7; breast cancer subjects, Lane 8; no DNA; Lane 9; Hind III digested DNA marker. Lanes 1, 2, 4, and 7 showed the amplification products of GSTM1 nucleotide sequences between exon 5 to exon 6. Lanes 3, 5 and 6 showed no PCR product (= null genotype).

The results of the present study are summarized in Table 1. The prevalence of the GSTM1 null genotype is 39.0 % in the normal control group which is confirm our previous report [18]. The frequency of the null genotype has been shown to vary among different groups [17, 21-24]. About 50% of the individuals in most Caucasian populations and other populations are homozygous for the GSTM1\*0 allele and lack of the GSTµ activity. However, the frequency of the null genotype in the studied population (Shiraz, Iran) is low, when compared with other studied populations. Because the GSTM1 located on human chromosome 1p13 [25], the lack of the GSTµ activity inherited as an autosomal recessive phenotype. There is no statistically differences  $(X^2 = 0.12; df = 1; p > 0.05)$  for the frequency of null genotype between males (35.7%) and females (39.0%) of healthy normal control groups (Table 1). The frequency of the null genotype was 50.8 % in patient group (Table 1). Comparison between the two studied groups showed that the observed difference was not significant ( $X^2 = 1.63$ , df = 1, *p* >0.05).

Table 1. Distribution of null- and non null-GSTM1 genotypes and development of breast cancer, stratified by selected characteristics

Subgroups (N)		GSTM1 null	Non-null	
Whole group		Go I MII IIuli		
Female controls (59)		23	36	
Male controls (56)	20	36		
Breast cancer patients (59)		30	29	
Age				
Age <50				
Female controls (44)		17	27	
Breast cancer patients (37)	20	17		
Age >50				
Female controls (15)		6	9	
Breast cancer patients (22)		10	12	
History of cigarette smoking	ng			
Never				
Female controls (57)		22	35	
Breast cancer patients (48)	25	23		
Ever				
Female controls (2)		1	1	
Breast cancer patients (11)	5	6		
Family history of malignar	ncy in first degree of 1	relatives		
No				
Female controls (55)		22	33	
Breast cancer patients (53)		27	26	
Yes				
Female controls	(4)	1	3	
Breast cancer patients	(6)	3	3	

Several studies have shown that GSTM1\*0 is associated with an increased risk of lung, bladder, stomach, larynx, and breast cancers and acute lymphocytic leukemia [10-18]. However, those studies did not find an association between GSTM1\*0 and breast cancer [17, 19].

Our data demonstrated that although the GSTM1 null genotype is more frequent in breast cancer cases than in community controls, this difference does not reach a statistical significant in the whole population under study. Our results are compatible to those obtained by other groups [17, 19], who studied on the large sample size of both control and patient groups [19].

The examination of GSTM1 genotypes in some stratified patient groups sometimes gave only weak statistical significance for some groups [12, 15, 26]; however, the overall pattern in those data indicated that the null genotype may be associated with a slightly increased risk for developing breast cancer. As shown in Table 1, the risk of breast cancer associated with GSTM1 genotypes, stratified by age, cigarette smoking, and family history of malignancy in first degree relatives, was not statistically significant. A history of cigarette smoking was statistically associated with increased risk of breast cancer ( $X^2 = 7$ ; df = 1; *p* <0.05).

In addition to polymorphism in phase II enzymes, genetic polymorphism in the phase I enzyme cytochrome P450 1A1 (CYP1A1) gene were correlated with an increased susceptibility to chemical carcinogenesis [27, 28]. CYP1A1 is involved in the activation of several procarcinogens [29]. Genetic variants in the CYP1A1 gene can result in an enhancement of the CYP1A1 activities [30].

There is a need to study biological and epidemiological aspects of breast cancer. This is required to elucidate the cooperative or possible antagonistic effect(s) of GSTM1 gene polymorphisms with other phase I or phase II enzymes, as well as the effect(s) of environmental exposure in breast carcinogenesis.

## ACKNOWLEDGEMENTS

The authors would like to thank Mrs. B. Shams, Mr. A. Zakeri, Mr. B. Faramarzi, and Mr. M.R. Zare for their skillful assistance. This work was supported by the Research Project (78-SC-1179-654) of Shiraz University.

#### REFERENCES

- 1. Kawajiri, K. and Fujii-Kuriyama, Y. (1991) P450 and human cancer. *Jpn. J. Cancer Res.*82: 1325-1335.
- Seidegard, J., Guthenberg, C., Pero, R.W. and Mannervik, B. (1987) The trans-stilbene oxideactive glutathione transferase in human mononuclear leukocytes is identical with the hepatic glutathione transferaseµ. *Biochem. J.246: 783-785.*
- 3. Hayes, J.D. and Pulford, D.J. (1995) The glutathione S-transferase family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. *Crit. Rev. Biochem. Mol. Biol.* 30: 445-600.
- Pemble, S., Schroeder, K.R., Spencer, S.R., Meyer, D.J., Hallier, E., Bolt, H.M., Kettever, B. and Tayler, J.B. (1994) Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. *Biochem. J.300: 271-276.*
- Seidegard, J., Vorachek, W.R., Pero, R.W. and Pearson, W.R. (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. *Proc. Natl. Acad. Sci. USA85: 7293-7297.*
- 6. Seidegard, J., DePierre, J.W. and Pero, R.W. (1985) Hereditaryinterindividual differences in the glutathione transferase activity towards transstilbene oxide in resting human mononuclear leukocytes are due to a particular isozyme(s). *Carcinogenesis6: 1211-1216*.
- Hayes, J.D. and Pulford, D.J. (1995) The glutathione S-transferase supergene family: regulation of GST and contribution of the isoenzymes to cancer chemoprevention and drug resistance. *Crit. Rev. Biochem. Mol. Biol.*31: 445-600.
- Lin, H.J., Han. C.Y., Bernstein, D.A., Hsiao, W., Lin, B.K. and Hardy, S. (1994) Ethnic distribution of the glutathione transferase Mu.1 (GSTM1) null genotype in 1473 individuals and application to

bladder cancer susceptibility. *Carcinogenesis15:* 1077-1081.

- 9. Board, P.G. (1981) Biochemical genetics of glutathione S-transferase in man. *Am. J. Hum. Genet.* 33: 36-43.
- Lafuente, A., Pujol. F., Carretero, P., Villa, J.P., and Cuchi, A. (1993) Human glutathione S-transferaseμ (GSTμ) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. *Cancer Lett.68: 49-54*.
- 11. Seidegard, J., Pero, R.W., Markowitz, M.M., Roush, G., Miller, D.G. and Beattie, E.J. (1990) Isoenzyme(s) of glutathione transferase (class mu) as a marker for susceptibility to lung cancer: a follow up study. *Carcinogenesis11: 33-36*.
- Helzlsover, K.J., Selmin, O., Huang-Han, Y., Strickland, P.T. Hoffman, S., Alberg, A.J., Watson, M., Comstock, G.W. and Bell, D. (1998) Association between glutathione S-transferase M1, P1 and T1 genetic polymorphisms and development of breast cancer. J. Natl. Cancer Inst.90: 512-518.
- Katoh, T., Nagata, N., Kuroda, Y., Itoh, H., Kawahara, A. and Kuroki, N. (1996) Glutathione Stransferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. *Carcinogenesis17:* 1855-1859.
- 14. Nazar-Stewart, V., Morsulsky, A.G., Eaton, D.L., White, E., Hornung, S.K. and Leng, Z.T. (1993) The glutathione S-transferase mu polymorphism as a marker for the susceptibility to lung carcinoma. *Cancer Res.53: 2313-2318.*
- Maugard, C.M., Charrier, J. and Bignon, Y.J. (1998) Allelic deletion at glutathione S-transferase M1 locus and its association with breast cancer susceptibility. *Chemico. Biol. Interactions111-112:* 365-375.
- Shea, T.C., Clafin, G., Comstock, K.E., Sanderson, B.J.S., Burstein, N.A., Keenan, E.J., Mannervik, B. and Henner, D. (1990). Glutathione transferase activity and isoenzyme composition in primary human breast cancers. *Cancer Res.50: 6848-6853*.
- Harada, S., Misawa, S., Nakamura, T., Tanaka, N., Ueno, E. and Nozoe, M. (1992) Detection of GST1 gene deletion by the polymerase chain reaction and its possible correlation with stomach cancer in Japanese. *Hum. Genet.* 90: 62-64.
- Saadat, I. and Saadat, M. (2000) The glutathione Stransferase mu polymorphism and susceptibility to acute lymphocytic leukemia. *Cancer Lett.* 158: 43-45.
- 19. Zhong, S., Wyllie, A.H., Barnes, D., Wolf, C.R. and Spurr, N.K. (1993) Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. *Carcinogenesis14:* 1821-1824.
- Newton, C.R. (1995) Mutational analysis: Known mutations. In: *PCR*: A practical approach. (McPherson, M.J., Hames, D. and Taylor, G.R.

eds.), IRL-Press, Oxford, U.K. pp.219-222.

- 21. Laisney, V., Cong, V., Gross, M.S. and Frezal J. (1984) Human genes for glutathione S-transferases. *Hum. Genet.*68: 221-227.
- 22. Strange, RC., Feulder G.C., Davis, B.A., Hume, R., Brown, J.A.H., Cotton, N. and Hopkinson, D.A. (1984) The human glutathione-S-transferase studies on the tissue distribution and genetic variation of GST1, GST2 and GST3 isozymes. *Ann. Hum. Genet.48: 11-20.*
- Board, P., Coggan, M., Johnsto, P., Ross. V., Suzuki, T. and Webb, G. (1990) Genetic heterogenecity of the human glutathione transferases. a complex of gene families. *Pharmacol. Ther.48: 357-369.*
- 24. Board, P.G. (1981) Gene deletion and partial deficiency of the glutathione S-transferase (ligandin) system in man. *FEBS Lett.135: 12-14*.
- Pearson, W.R., Vorachek, W.R. Xu, S.J., Berger, R., Hart, I., Vannais, D. and Patterson, D. (1993) Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome

1p13. Am. J. Hum. Genet. 53: 220-233

- Ambrosone, C.B., Freudenheim, J.L., Graham, S., Marshall, J.R., Vena, J.E. and Brasure, J.R. (1995) Cytochrome P<sub>450</sub>1A1and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. *Cancer Res.* 55: 3483-3485
- 27. Guengerich, F.P. (1988) Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. *Cancer Res.*48: 2946-2954.
- 28. Gonzales, F.J. (1990) The molecular biology of cytochrome P450s. *Pharmacol. Res.*45: 243-288.
- McManus, M.E.M., Burgesss, W.M., Veroneses, M.E., Huggett, A., Quattrochi, L.C. and Tuckey, R.H. (1990) Metabolism of 2-acetylaminofluorene and benzo[a] pyrene and activation of food-derived heterocyclic amine mutagens by human cytochrome p-450. *Cancer Res.50: 3367-3376*.
- Crofts, F., Taioli, E., Trachman, J., Cosma, G.N., Currie, D. and Tonioli, P. (1994) Functional significance of different human CYP1A1 genotypes. *Carcinogenesis 15: 2961-2963*.